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Diagnostic journey and impact of enzyme 
replacement therapy for mucopolysaccharidosis 
IVA: a sibling control study
Can Ficicioglu1* , Dena R. Matalon2, Nicole Luongo1, Caitlin Menello1, Tracy Kornafel1 and Andrew J. Degnan3
Abstract 
Background: Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive 
lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Early recogni-
tion, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead 
to improved outcomes and reduced mortality.
Methods: This report documents the diagnostic journey and treatment with ERT of three siblings with MPS IVA. 
Clinical outcome measures included growth, endurance, imaging, cardiac, respiratory, ophthalmology, and laboratory 
evaluations.
Results: Three siblings, diagnosed at 14.7, 10.1, and 3.2 years of age, demonstrated clinical improvement with weekly 
infusions of 2.0 mg/kg elosulfase alfa  (Vimizim®, BioMarin Pharmaceutical, Novato, CA, USA). Patient 1 (oldest sibling) 
and Patient 2 (middle sibling) experienced a diagnostic delay of 8 years 7 months and 4 years after symptom onset, 
respectively. All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion, 
and respiratory function after 30 months of ERT. The treatment was well tolerated without any adverse events.
Conclusions: This case series highlights the importance of early recognition of the clinical and imaging findings 
that are initially subtle in MPS IVA. Early treatment with ERT is necessary to slow irreversible disease progression and 
improve patient outcomes. The oldest sibling experienced improvements in mobility despite severe symptoms result-
ing from a late diagnosis. When evaluating patients with skeletal anomalies, imaging multiple body regions is recom-
mended. When findings such as anterior beaking of vertebrae or bilateral femoral head dysplasia are present, MPS IVA 
should be included in the differential diagnosis. Newborn screening must be considered for early detection, accurate 
diagnosis, and initiation of treatment to reduce morbidity.
Keywords: Mucopolysaccharidosis IVA, Enzyme replacement therapy, Anterior beaking, Platyspondyly, Diagnosis, 
Treatment
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Background
Mucopolysaccharidosis (MPS) IVA, also referred to as 
Morquio A syndrome, is a rare autosomal recessive lys-
osomal storage disorder caused by a deficiency in the 
enzyme N-acetylgalactosamine-6-sulfatase (GALNS) 
[1–4]. Impaired degradation of the glycosaminoglycans 
(GAGs) keratan sulfate and chondroitin 6-sulfate stem-
ming from reduced GALNS activity results in unde-
graded GAGs in lysosomes across multiple tissues and 
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organs, particularly in chondrocytes [3]. MPS IVA typi-
cally presents with bony abnormalities, short stature, and 
skeletal dysplasia [3, 5, 6]. Other findings include res-
piratory insufficiency, cardiovascular abnormalities, and 
dental impacts [5, 7]. Due to the progressive and hetero-
geneous nature of the disease and its variable presenta-
tion, early diagnosis can be challenging [1, 8]. However, 
prompt recognition, accurate diagnosis, and proper man-
agement of the disorder are necessary to improve patient 
outcomes [8].
Prior to the approval of elosulfase alfa  (Vimizim®, 
BioMarin Pharmaceutical, Novato, CA, USA) as an 
enzyme replacement therapy (ERT) for patients with 
MPS IVA [9, 10], the treatment of MPS IVA mainly con-
sisted of supportive therapy [11]. In a randomized, dou-
ble-blind, placebo-controlled phase 3 pivotal trial that 
included patients ≥ 5  years of age, treatment with elo-
sulfase alfa was well tolerated and resulted in a consid-
erable improvement in endurance (6-min walk distance 
[6MWD]), substantial reduction in urinary keratan sul-
fate, and improvements in pulmonary function, height, 
and growth compared with placebo [11]. In a phase 2, 
open-label study in patients younger than 5  years of 
age, elosulfase alfa was well tolerated and resulted in a 
reduction of urinary keratan sulfate and a trend toward 
improvement in growth [12]. Previously published case 
reports of siblings with MPS disorders have shown that 
earlier treatment and management of these disorders 
results in improved outcomes [13–15].
Evidence of the impact of treatment with ERT and 
other interventions is needed to help inform healthcare 
providers of the importance of early diagnosis and to sup-
port newborn screening initiatives. In this case report, 
we describe three African American siblings who pre-
sented with similar symptoms at 5, 5, and 3 years of age, 
respectively. The two older siblings experienced a delay in 
diagnosis after the onset of symptoms, while the young-
est sibling was suspected to have the same condition. The 
diagnosis for all three siblings was confirmed as MPS 
IVA via molecular genetic analysis and biochemical data. 
The differences in the siblings’ clinical courses highlight 
the importance of early recognition of MPS IVA because 
of the progressive nature of this disorder; specifically, 
understanding and recognizing the skeletal abnormalities 
of MPS IVA early will enable timelier diagnosis and treat-
ment, which could help reduce mortality and morbidity.
Methods
The three siblings with MPS IVA presented at Children’s 
Hospital of Philadelphia (CHOP) in the United States 
for clinical care. The siblings were born to non-consan-
guineous parents. Parental consent was obtained from 
both parents to use the patients’ medical data and pho-
tographs. All radiographs, magnetic resonance imaging 
(MRI), genetic testing, and other results were performed 
clinically and reviewed. All three patients initiated ERT 
(elosulfase alfa, BioMarin Pharmaceutical Inc., Novato, 
CA, USA) at the same time (Patient 1, 14.7 years of age; 
Patient 2, 10.1 years of age; Patient 3, 3.2 years of age).
Results
Clinical manifestations and laboratory evaluations
The clinical course of the three siblings is summa-
rized in Table  1. All patients presented with similar 
symptoms at different ages. Patient 1 (oldest sibling) 
was noted to have a limp and endorsed hip pain at 
5  years of age; he was diagnosed with bilateral Legg-
Calve-Perthes disease (Fig.  1). At 7  years of age, he 
was referred to orthopedics for further evaluation 
and treatment at Children’s Hospital of Philadelphia 
(CHOP). Upon examination at the clinic, he presented 
with an abnormal wide gait with the lower legs placed 
in valgus; tenderness on the bilateral greater tro-
chanter; and full range of motion, but with mild ten-
derness, on both knees and ankles. He underwent hip 
surgery and experienced a prolonged recovery with 
worsening of his symptoms. After his recovery, he 
was lost to follow-up and was seen again by orthope-
dics at CHOP at 11 years of age. At that time, he was 
unable to walk independently and was noted to have 
Table 1 Clinical course for Patients 1, 2, and 3 with MPS IVA
ERT enzyme replacement therapy, MPS IVA mucopolysaccharidosis type IVA
Patient 1 Patient 2 Patient 3
Current age 17 years, 8 months 13 years, 1 month 6 years, 2 months
Type of genetic analysis Whole-exome sequencing Whole-exome sequencing Targeted GALNS sequencing
Results of GALNS gene analysis  c. 964G > C, p. A322P (paternally inherited, novel missense, variant of unknown significance)
 c. 611A > G, p. N204S (maternally inherited, novel missense, variant of unknown significance)
Age at onset of symptoms 5 years 5 years 3 years
Age at diagnosis 14 years, 7 months 10 years 3 years, 1 month
Age at initiation of ERT 14 years, 8 months 10 years, 1 month 3 years, 2 months
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a wide-based stance with increased weakness. Pel-
vis radiographs over time demonstrated progressive 
destructive change of the hips (Fig. 2). His progressive 
weakness prompted a referral to the neuromuscular 
clinic, and electromyography findings were sugges-
tive of mild myopathy. Radiographs and MRIs of the 
spine revealed multiple abnormalities, with prominent 
middle third spine vertebral involvement, consist-
ing of prominent anterior beaking, posterior endplate 
concavities, and mild platyspondyly (Fig.  3). Spondy-
loepiphyseal dysplasia was suspected due to the com-
bination of proximal femoral epiphyseal abnormalities, 
odontoid hypoplasia (Fig.  4), and platyspondyly, but 
genetic sequencing and deletion/duplication stud-
ies of COL2A1 (collagen type II alpha 1) and SEDL 
(spondyloepiphyseal dysplasia tarda) were negative. In 
retrospect, other radiographic features, including ante-
rior vertebral beaking and metacarpal abnormalities 
(Fig.  5), favored MPS IVA. At 5  years of age, Patient 
2 (middle sibling) was noted to experience the same 
pattern of clinical signs and symptoms as Patient 1. 
A skeletal survey was completed, which showed sym-
metrically abnormal femoral heads, radial and ulnar 
epiphyses, and carpal bones. Additionally, the lumbar 
vertebrae were noted to be slightly flattened and bullet 
shaped. Following diagnosis of the two older brothers, 
Patient 3 (youngest sibling) was diagnosed through 
family screening. The parents observed his wide-based 
gait at around 2.5  years of age, but the symptom was 
not brought to medical attention until diagnosis of his 
older siblings.
Patients 1 and 2 were referred for whole-exome 
sequencing at 14 and 9 years of age, respectively, which 
revealed compound heterozygous variants in the GALNS 
gene (Table  1). Enzyme testing revealed low GALNS 
activity. Urine GAG quantification revealed elevated 
GAGs, specifically chondroitin sulfate and keratan sul-
fate. Targeted-gene sequencing confirmed the diagno-
sis in Patient 3. Patient 3 was the least severely affected, 
with subtle differences in his skeletal survey and present-
ing with a slightly abnormal gait. The numerous skeletal 
abnormalities noted radiographically and reduced walk-
ing ability of Patient 1 highlight the progression of dis-
ease (Fig. 6).
The three siblings were started on intravenous infu-
sions of elosulfase alfa at a dose of 2.0 mg/kg/week. The 
progression of clinical signs, symptoms, and laboratory 
studies in response to ERT after 30 months are summa-
rized in Table 2.
Fig. 1 Anteroposterior radiograph of hips and pelvis in Patient 
1 at 6 years of age shows bilateral sclerotic, fragmented, and 
flattened proximal femoral epiphyses (asterisks), irregular acetabula 
(arrowheads), and coxa valga deformities. The patient was initially 
diagnosed with Legg–Calve–Perthes disease; in retrospect, acetabular 
irregularities and coxa valga would not be typical in this condition
Fig. 2 Representative serial radiographs of the proximal right femur of Patient 1 over time show progressive flattening of the epiphysis, 
concomitant widening of the proximal metaphyses, and increased irregularity of the acetabula resulting in compensatory pseudarthrosis-like 
formation
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Endurance
After undergoing 30  months of ERT, all three patients 
showed an improvement in endurance, as measured by 
the 6-min walk test (6MWT). After 5  months of treat-
ment, Patient 1 was unable to walk without the use of a 
walking aid and was only able to walk 50 m with the use 
Fig. 3 Lateral radiographs and MRIs of the thoracic spine in the three siblings. a In Patient 1, lateral thoracic spine radiograph (left) at 10 years of 
age shows relatively moderate vertebral body height loss (platyspondyly) and anterior vertebral body beaking, most prominent in the mid-to-lower 
thoracic spine (arrowheads). Sagittal T2-weighted MRI of the thoracic spine (right) shows moderate platyspondyly with prominent anterior beaking 
of multiple thoracic and upper lumbar vertebral bodies (arrowheads). The patient was initially diagnosed with spondyloepiphyseal dysplasia on 
the basis of clinical presentation, platyspondyly, and femoral epiphyseal abnormalities on imaging, although anterior beaking in the middle third of 
the spine is highly suggestive of MPS IVA, and vertebral flattening is not as prominent as would be expected in spondyloepiphyseal dysplasia. b In 
Patient 2, lateral thoracic spine radiograph at 6 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies (arrowheads). Sagittal 
T2-weighted MRI of the thoracic spine at 10 years of age (right) shows anterior vertebral body beaking (arrowheads) with mild vertebral height 
loss without platyspondyly. Presence of anterior vertebral body beaking in this case is strongly suggestive of MPS IVA. c In Patient 3, lateral thoracic 
spine radiograph at 3 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies without significant vertebral body height loss. 
Sagittal T2-weighted MRI of the thoracic spine at 5 years of age (right) highlights anterior vertebral body beaking. As with this patient’s siblings, 
anterior vertebral body beaking supported the diagnosis of MPS IVA
Page 5 of 10Ficicioglu et al. Orphanet J Rare Dis          (2020) 15:336  
of bilateral forearm crutches during the 6MWT. How-
ever, after 30 months of ERT, Patient 1 was able to walk 
unassisted for 300  m. The 6MWT results of Patients 2 
and 3 were 265 m and 175 m, respectively, after 5 months 
of ERT. The 6MWT distances increased to 425  m after 
30 months for Patient 2 and 290 m after 15 months for 
Patient 3.
Clinical measures of skeletal growth and function
The height, weight, and BMI of all three patients 
increased from baseline after 30 months of ERT; of note, 
the largest increase in percentiles for both weight and 
height was found in Patient 3 (Table 2). Patient 1’s height 
was 165.3 cm (7th percentile), and his weight was 65.3 kg 
(51st percentile) 30  months after starting ERT. After 
starting ERT, he gained weight (from the 39th percentile 
to the 51st percentile), and his BMI increased (from 48th 
percentile to the 78th percentile). Although he gained 
4  cm, his height percentile was not preserved, decreas-
ing from the 25th to the 7th percentile. Patient 2’s height, 
weight, and BMI were preserved, with his height being 
151.5  cm (43rd percentile), weight being 37.1  kg (20th 
percentile), and BMI being 15.8  kg/cm2 (11th percen-
tile) at 30 months post-treatment. Patient 3’s height was 
116.4 cm (74th percentile), his weight was 27.3 kg (98th 
percentile), and his BMI was 19.9 kg/cm2 (99th percen-
tile) at 30 months post-treatment. The height percentile 
of Patient 3 increased from the 60th to the 74th percen-
tile, his weight increased from the 87th to the 98th per-
centile, and his BMI increased from the 91st to the 99th 
percentile.
Joint range of motion (ROM) was assessed in 
the hips, knees, and ankles. Patient 1 experienced 
Fig. 4 Sagittal T2-weighted TSE MRI of the cervical spine of Patient 
1 at 10 years of age shows dysplastic odontoid process of C2, with 
irregular sclerosis and posterior migration of the tip of the dens 
(asterisk)
Fig. 5 Radiographic features of the hand in the three siblings supportive of MPS IVA. a Patient 1 at 6 years of age showed prominent shortening 
of the fourth and fifth metacarpals (asterisks) with proximal pointing of the fifth metacarpal (arrowhead) and widening of the first metacarpal. b 
Patient 2 at 6 years of age showed proximal pointing of the fifth metacarpal (arrowhead) and irregular carpal bones (asterisk). Notably, this patient’s 
metacarpal abnormalities were much less conspicuous compared with those of his older brother (Patient 1) at the same age. c Patient 3 at 3 years 
of age showed proximally shortened, widened metacarpals with proximal pointing of the second and fifth metacarpals (arrowheads)
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improvement (> 5°) in bilateral hip abduction, left 
hip internal rotation, bilateral knee extension, and 
bilateral ankle dorsiflexion with the knee flexed after 
5–30  months of ERT; right hip internal rotation 
remained unchanged. In Patient 2, similar improve-
ments were seen in left hip internal and external rota-
tion, left ankle dorsiflexion with knee extended, and 
bilateral popliteal angles after 5–30  months of ERT. 
Improvements to right ankle dorsiflexion with knee 
extended were minor (< 5°), and right hip rotation was 
reduced (from 20° before ERT to 10° after 30  months 
of ERT for internal rotation and from 30° before ERT 
to 5° after 30  months of ERT for external rotation). 
In Patient 3, bilateral ankle dorsiflexion with knee 
extended ROM and bilateral popliteal angles improved 
after 30 months of ERT.
Prior to initiation of ERT, Patient 1 was unable to 
walk independently and unable to remain in standing 
position. Improvement in mobility was observed after 
30 months of ERT, with the patient being able to walk 
without assistance for 300 m. Additional files 1 and 2 
demonstrates this improvement in mobility.
Cardiopulmonary evaluation
Initial cardiac evaluation was performed using an 
echocardiogram. There were no valve abnormalities or 
structural defects identified, and both left and right ven-
tricles were of normal size with normal systolic short-
ening for all three patients before the initiation of ERT. 
There were no changes in their echocardiography find-
ings or cardiac evaluations after 20 months of ERT.
Pulmonary function was evaluated using spirometry, 
and results were available for Patients 1 and 2. Prior to 
ERT, Patient 1 demonstrated 150% and 121% of predicted 
value for forced vital capacity (FVC) and forced expira-
tory volume in 1 s (FEV1), respectively. After 20 months 
of ERT, he had 157% and 121% of predicted value for 
FVC and FEV1, respectively. Patient 1’s FEV1/FEV was 
moderately increased and forced expiratory flow between 
25 and 75% of FVC  (FEF25–75) mildly decreased. Prior to 
ERT, Patient 2 had 71% of predicted value for both FVC 
and FEV1. After 20  months of ERT, his FVC and FEV1 
predicted values increased to 85% and 78%, respectively. 
His FEV1/FEV was moderately decreased and  FEF25–75 
was mildly increased. Patient 2 reported experiencing 
Fig. 6 Physical examination of the siblings. Patient 1 at 14 years of age, Patient 2 at 9 years of age, and Patient 3 at 3 years of age. Lordotic posture 
can be noted in all three patients. Prior to starting ERT, all three siblings showed skeletal abnormalities and walking impairment, which were more 
advanced in the oldest sibling (Patient 1)
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Table 2 Comparison of  clinical signs, symptoms, and  laboratory studies of  the  three siblings at  baseline 
and after 30 months of ERT
6MWD 6-min walk distance, BMI body mass index, CDC US Centers for Disease Control and Prevention, ERT enzyme replacement therapy, FEF25–75 forced expiratory 
flow between 25 and75% of FVC, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GAG glycosaminoglycan, OSA obstructive sleep apnea, ROM range of 
motion
a Initial joint ROM and 6MWD evaluations were conducted after initiation of treatment (Patients 1 and 2, 5 months; Patient 3, 3 months)
b CDC Clinical Growth Charts for 2–20 years of age
c Evaluation after 20 months of ERT
d Ambulation with bilateral forearm crutches in 59 s
e Evaluation after 30 months of ERT
f Distance walked in 2.75 min due to refusal to continue
Patient 1 Patient 2 Patient 3
Before ERT After ERT Before ERT After ERT Before ERT After ERT
6MWD,a m 50d 300 265 425 175f 290e
Height, cm 
 (percentileb)
161.4 (25) 165.3 (7) 137.5 (44) 153.1 (43) 97.0 (60) 117.2 (74)
Weight, kg 
 (percentileb)
50.8 (39) 65.3 (51) 27.9 (21) 37.1 (20) 16.6 (87) 27.3 (98)
BMI, kg/cm2 
 (percentileb)
19.5 (48) 23.9 (78) 14.8 (11) 15.8 (11) 17.6 (91) 19.9 (99)
Joint ROM, a degrees
 Hip abduction R: 10 R:  20e R: 20 – – R: 55
L: 15 L:  20e L: 20 L: 55
 Hip internal rota-
tion
R: 10 R:  10e R: 30 R:  40e – R: 60
L: 5 L:  15e L: 30 L:  10e L: 60
 Knee extension R: − 35 R: − 20 – R: 0 – R: 0
L: − 55 L: − 30 L: − 15 L: 0
 Ankle dorsiflexion 
with knee flexed
R: 8 R:  15e – – – –
L: 10 L:  15e
 Ankle dorsiflex-
ion with knee 
extended
– R: 0 R: 8 R: 10 R: 10 R: 15
L: 5 L: 5 L: 10 L: 10 L: 15
 Popliteal angle – – R: 15 R: 25 R: 30 R: 0
L: 15 L: 35 L: 30 L: 0
Cardiac  functionc No significant 
findings








 FVC,c % 150 157 71 85 – –
 FEV1,c % 121 121 71 78 – –
 FEV1/FVCc 71 79 101 81 – –
 FEF25–75,
c % 76 70 41 46 – –
 Polysomnography – Snoring, no 
evidence of 
significant OSA
No evidence of 
OSA or restrictive 
lung disease
Normal breathing No evidence of 
OSA or restrictive 
lung disease
Snoring, no evidence 
of substantial OSA






7.77 2.87e 9.61 8.01e 21.2 14.19e
 Keratan sulfate, 
μg/mol creati-
nine
5.35 2.97e 7.21 6.33e 16.6 9.95e
Page 8 of 10Ficicioglu et al. Orphanet J Rare Dis          (2020) 15:336 
shortness of breath during activity and excessive daytime 
somnolence when evaluated after 15 months of ERT. At 
20  months of ERT, polysomnography showed snoring 
with no evidence of significant obstructive sleep apnea in 
Patients 1 and 3. Patient 2 had normal breathing during 
sleep.
Ophthalmology
Both Patient 1 and Patient 2 had bilateral mild corneal 
haze prior to ERT, which remained unchanged after 
30  months of ERT. In Patient 3, bilateral subtle cor-
neal haze improved to diffuse, fine corneal haze after 
30 months of ERT.
Urinary glycosaminoglycan levels
In all three patients, urinary chondroitin sulfate (g/
mol creatinine) and keratan sulfate (μg/mol creatinine) 
decreased with ERT (Table 2).
ERT dosage and adverse reactions
All three patients received weekly infusions of elosulfase 
alfa at a dose of 2.0 mg/kg, and treatment was well toler-
ated throughout its duration without any adverse events.
Clinical course of the three patients with MPS IVA
Patients with MPS IVA usually present with clinical signs 
or symptoms at the end of the first year of life. Most 
who present with classical symptoms are diagnosed at 
2–3  years of age due to disproportional short stature, 
waddling gait, pectus carinatum, and frequent respira-
tory infections.
Diagnostic delay: Patient 1 presented with limp and 
hip pain around 5 years of age. He was seen by orthope-
dics at an outside institution and diagnosed with bilat-
eral Legg-Calve-Perthes disease of unknown etiology. 
He was referred to orthopedics at the CHOP at 7 years 
of age, where a work-up for Legg-Calve-Perthes disease 
was undertaken and tested negative, including normal 
alpha globin, prothrombin, and Factor V Leiden genetic 
testing. His orthopedic surgeon questioned the diagnosis 
and referral to neuromuscular was recommended, given 
the progression of his symptoms and weakness. However, 
due to insurance issues, a consultation was not com-
pleted, and the patient was lost to follow-up for several 
years. He re-presented to care when his younger brother 
(Patient 2) developed the same symptoms. Further evalu-
ation of the case by a neurologist and clinical geneticist 
lead to sending for whole-exome sequencing, which 
revealed compound heterozygous variants in the GALNS 
gene. In this case, the protracted diagnostic odyssey was 
likely due to the initial subtlety of findings and lack of 
knowledge about symptoms and signs of this rare, inher-
ited metabolic disease among many physicians. Typically, 
disproportionately short stature has been considered a 
hallmark of this disorder. In this case series, Patients 1 
and 2 were initially of normal height. Thus, a high index 
of suspicion and diligent examination of radiographs is 
required.
Treatment response: Patient 1 was severely affected at 
the time of diagnosis. He was unable to stand up with-
out assistance and only capable of taking a few steps with 
assistance. After starting ERT, his endurance improved, 
and he was able to stand up independently; after 
6  months of therapy, he started walking with crutches. 
One year after starting ERT, he started walking unas-
sisted. Video 1 highlights his ability to walk unassisted 
during the 6MWT. His 6MWD increased significantly. 
His urine GAGs decreased, and his cardiac, pulmonary, 
and ophthalmological findings were stable. Due to the 
late diagnosis and severe skeletal involvement, his height 
increased only 4 inches in 30 months on ERT.
Patient 2 presented with a wide-based gait and hip pain 
at around 5 years of age. His symptoms remained more 
or less stable for the next 4 years, although each year, he 
had increased difficulty with walking. When he was diag-
nosed at 9  years of age, his 6MWD was 265  m, which 
increased to 425 m after 30 months of ERT. His walk is 
shown in Video 2. His height remained preserved around 
the 40th percentile.
Patient 3 was 3  years old at the time of diagnosis 
through family screening. Parents recalled that they 
noticed a wide-based gait beginning at around 2.5 years 
of age but were not concerned until his older broth-
ers were diagnosed with MPS IVA. His waddling gait 
remained stable after the ERT. His 6MWD increased 
from 175 to 290  m, but the accuracy of this measure-
ment was compromised because of poor cooperation. 
His height increased from the 60th to the 74th percentile.
Discussion
The efficacy and safety of elosulfase alfa in treat-
ing MPS IVA have previously been demonstrated in 
patients ≥ 5  years and < 5  years of age. In this report, 
three siblings with MPS IVA initiated weekly infusions of 
elosulfase alfa starting at 14.7, 10.1, and 3.2 years of age, 
respectively. Thirty months of ERT was well tolerated and 
led to improvements in endurance (6MWD), growth, and 
joint ROM, and reduction in urinary GAGs, consistent 
with prior clinical studies.
Early diagnosis of MPS IVA is important to initiate 
treatment with ERT as soon as possible, as skeletal mani-
festations are considered irreversible. In this report, the 
three siblings received ERT at different stages of MPS 
IVA; Patient 1 had the most-severe presentation and 
was unable to walk independently at the start of treat-
ment, whereas Patients 2 and 3 have developed some 
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radiographic features of MPS IVA but have not yet expe-
rienced severe impairment to their mobility. While all 
three patients experienced improvement in clinical out-
comes after 30 months of ERT, Patient 1 showed remark-
able improvement in being able to walk unassisted, 
albeit not to the same level of his siblings who initiated 
treatment earlier. These three cases show us that ERT 
can reverse some progressive symptoms while slowing 
others.
The clinical presentation of MPS IVA is heterogeneous, 
and initial findings are subtle. This makes the diagnosis 
a challenge and can lead to substantial delays, as under-
scored by the diagnostic journey of Patient 1 [1, 8]. This 
case series highlights the importance of early recognition 
of the clinical and imaging findings of MPS IVA, espe-
cially considering the progressive nature of this disorder. 
The characteristic, progressive radiographic features in 
the pelvis, spine, and hand, as documented in this study, 
are key for MPS IVA diagnosis and follow-up testing. 
Thus, when evaluating patients with skeletal anomalies, 
imaging multiple body regions is recommended. With 
findings such as anterior beaking of vertebrae or bilateral 
femoral head dysplasia, MPS IVA should be included in 
the differential, as early treatment can reduce morbidity.
Despite the three siblings initially presenting with 
similar signs and symptoms, Patient 1 had a more-severe 
functional disability due to 9-year diagnostic delay. 
Improving awareness and recognition of MPS IVA will 
enable earlier diagnosis and treatment [8]. Evidence- and 
consensus-based management guidelines for MPS IVA 
for healthcare professionals have recommended imple-
mentation of newborn screening for MPS IVA to allow 
very early ERT to help slow the progression of the disease 
and improve outcomes [1]. Long-term ERT (elosulfase 
alfa, 2.0 mg/kg weekly IV infusions) is recommended in 
all patients with a confirmed MPS IVA diagnosis [1].
Conclusion
Treatment with elosulfase alfa ERT in three siblings 
with MPS IVA was effective in improving clinical out-
comes and was well tolerated. The variable clinical 
presentation, delay in diagnosis, and progressive nature 
of MPS IVA, as demonstrated by these three siblings, 
highlight the importance of improving awareness and 
recognition of the disease’s early signs and symptoms. 
The initiation of ERT in these siblings improved their 
endurance, reduced their pain, and improved their 
ranges of motion. In the younger siblings, height was 
preserved or improved. Additionally, in the youngest 
sibling, ophthalmologic findings improved. The young-
est and middle siblings continue to walk independently, 
and the oldest sibling can now walk with crutches or 
unassisted for 300  m. This highlights the substantial 
effect of ERT in slowing disease progression and 
improving patient outcomes even in the late-diagnosed 
patient. Newborn screening for MPS IVA is necessary 
to prevent diagnostic delay and initiate treatment as 
early as possible to achieve better clinical outcomes.
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